Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, ...

(Reuters) - Moderna Inc said on Wednesday its experimental COVID-19 vaccine induced immune responses in older adults similar to those in younger participants, offering hope that it will be effective ...

(NewsNation Now) — Moderna said Tuesday its COVID-19 vaccine strongly protects kids as young as 12, a step that could put the shot on track to become the second option for that age group in the United ...

"We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 Vaccine should be protective against these newly detected variants," Moderna CEO Stéphane Bancel said in ...

Moderna's MRNA.O mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on ...

March 3 (Reuters) - Moderna has ⁠agreed ⁠to pay Genevant Sciences, a ⁠subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology ...

Advisers to the Food and Drug Administration have thrown their support behind an experimental flu shot from Moderna, heightening the chance that the vaccine could soon complete a dramatic regulatory ...

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.